Bradda Head Lithium exceeds targets, secures US$3 million royalty and moves closer to production. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Staying strong ,update in two weeks time
So the CFO’s wife sold 60k shares and bought back in her ISA. That would be about twice the ISA allowance so presumably had to sell something else in her ISA. You want not make that sort of move if you weren’t expecting to make substantial gains in future. I think. The market and other investors like Mills and Griffiths may have underestimated the further growth here
Looks like the tide has turned into the next trade update next month,would be nice for another special divi
All resolutions passed. Ex dividend tomorrow
Totally get the temptation and sense in top slicing. I’m banking on that decision being taken for me in due course with a buyout. In the meantime hoping they offload more of that cash on shareholders . May not get news on home test kit for a while yet but there could be other uplifts with upgrade of existing kit and what would be quite ironic, whispers of COPD testing . Still plenty of positives
In 2022 the company changed its name from Circassia Group plc to NIOX Group plc.
BEP 37.7p.
12 trades since 20/6/16 first buy 90p sold all of them 29/6/16 for 97p , so might of been quick trade idea at first .
Back in 6/9/17 at 80p not a good move even now.
Thank God I averaged down twice at lows in June 2019 in hindsight.
But did not look such a good move at the 17/3/20 12.93p low by 4/5/20 they were 47p Covid time.
Time you only chance.
Bstd
Sold half of holding for 73p.. 12.30pm , 72p was the 5 year high.
Closed 74.
5 Analysts expect the price to increase by 8% , to 78p
Generally Volumes are increasing across many stocks which is a healthy sign. Certainly it has lifted Niox 15 percent recently. What I don’t quite understand are the many multi hundred thousand share trades that don’t appear to shift the dial anymore than trades of a few hundred. Don’t suppose we will get much more from the Agm but possible news on COPD and special dividend would maybe send the dial spinning
And now I understand there is a possibility Niox will be used for COPD diagnostics, which is ironic as that was what led to the dissolution of their partnership with Astra. Just keep getting better
The mysterious multi hundred thousand buy trades continue while forty 66p bot trades drags the price down!
2 million buy! Is it for the dividend or something more?
Dividend set for May/June on shareholder approval. Anyone going to object? Maybe then get further news on another special. I can’t seen the directors having emotions for takeovers, more ambitious to get the company sold and retire hopefully. Great job though
Some thumping trades this morning. Two well over a million and two at half a million. I was wondering about the surplus cash. Ip dividend is not overly generous. Singer say there remains the opportunity for second special dividend on top of the maiden dividend. Be nice if they could manage both and the takeover!
What the results do show is the impressive impact the senior management team have had in the last 3+ years to get the business to this strong and growing position. It does look like there may be a changing of the guard - Michael Roller is going part time; and you wonder if Ian Johnson is considering how long he will remain with the business (he is 70). AstraZeneca remain a major shareholder - and active investor Richard Griffiths still retains a 24% holding. SB
SB. Indeed the hidden asset of 600 million tax credit as Chris Mills put it. Plus 22.5 million cash as of end of february. Valuation doesnt look stretched to me for 18 % growth compounding. The market is also growing possibly to 400 million in next decade. The improvement and cost of drugs also necessitates the accuracy of Feno for which Niox are currently in a field of their own.
*oogle.....
Morning ooggle - decent position when you compare the company to where it was a few years ago. At a market cap of c.£270m this looks fully valued for me at present based on operating profit (£4.6m). What is starting to make a major impact is the tax credit - which contributed more profit (£5.4m) than actual trading operations - and there's a lot more to come from that source - and that's an area where potential suitors may look to take advantage of. SB
Confirmed 23 year results from January. 18 percent revenue growth. 1p dividend confirmed for 2023 but no date set yet. Nearly 20 million cash balance plus whatever assets year (possibly another 5 million) . Lungfit approval in USA to add 10 million dollars over 3 years. Strong point made about the importance of the uptake of FeNo testing with better and more expensive drugs becoming available. Asset value just over 80 million. All in all the stock set to become very undervalued if progress only continues at this pace but of course likely to accelerate further with development of home kit and the larger updated version of current diagnostic machine. Still early days for a bid maybe, but depends how much quicker a larger company could place and develop their products. I would imagine the current sp would be largely supported by todays update, but who can tell in this mad market!
Apologies replying to Silverblade. Also should have said only 800,000 ISA accounts fully invested. Good to have some company. Getting a bit worried everyone had sneaked off! I suppose we are a bit egg in one basket but it’s the hell of an egg
Corry . Certainly not complaining about an extra ISA. It’s just the idea that it will help investment in British stocks is not very convincing or well thought through for a man of Hunt’s calibre and chaperones. How many investors who don’t already own British stock are likely to invest in them because of this extra allowance. There are only about 800,000 ISAinvestment accounts currently anyway
Hopefully the UK market will have got out the doldrums long before then on it's own, or half of it already sold off to PE at undervalue before the £5k even has a chance.
Might be in place by end of next tax year. From the Treasury consultation doc:
"4.1 Following consultation, the government will confirm the final scheme design before bringing forward any necessary legislation. It will also set out more detail on the timeframe for implementation and the necessary reporting tools."
Consultation is running from 6 March to 6 June 24.
On the other hand.....isa allowance is now £25k a year.....so its not all grim oogle! SB